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Chaoqin Xie, MD, Jun Hu, PHD, Lukas J. Motloch, MD, PHD, Basil S. Karam, BS, Fadi G. Akar, PHDABSTRACTFro
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MaBACKGROUND Type 2 diabetes mellitus (T2DM) is associated with an enhanced propensity for ventricular
tachyarrhythmias (VTs) under conditions of metabolic demand. Activation of mitochondrial adenosine triphosphate-
sensitive potassium (KATP) channels by low-dose diazoxide (DZX) improves hypoglycemia-related complications,
metabolic function, and triglyceride and free fatty acid levels and reverses weight gain in T2DM.
OBJECTIVES In this study, we hypothesized that DZX prevents ischemia-mediated arrhythmias in T2DM via its putative
cardioprotective and antidiabetic property.
METHODS Zucker obese diabetic fatty (ZO) rats (n ¼ 43) with T2DM were studied. Controls consisted of Zucker lean
(ZL; n ¼ 13) and normal Sprague-Dawley (SprD; n ¼ 30) rats. High-resolution optical action potential mapping was
performed before and during challenge with no-ﬂow ischemia for 12 min.
RESULTS Electrophysiological properties were relatively stable in T2DM hearts at baseline. In contrast, ischemia
uncovered major differences between groups, because action potential duration (APD) in T2DM failed to undergo pro-
gressive adaptation to ischemic challenge. DZX promoted the incidence of arrhythmias, because all DZX-treated T2DM
hearts exhibited ischemia-induced VTs that persisted on reperfusion. In contrast, untreated T2DM and controls did not
exhibit VT during ischemia. Unlike DZX, pinacidil promoted ischemia-mediated arrhythmias in both control and T2DM
hearts. Rapid and spatially heterogeneous shortening of APD preceded the onset of arrhythmias in T2DM. DZX-mediated
proarrhythmia in T2DM was not related to changes in the messenger ribonucleic acid expression of Kir6.1, Kir6.2, SUR1A,
SUR1B, SUR2A, SUR2B, or ROMK (renal outer medullary potassium channel).
CONCLUSIONS Ischemia uncovers a paradoxical resistance of T2DM hearts to APD adaptation. DZX reverses this
property, resulting in rapid and heterogeneous APD shortening. This promotes reentrant VT during ischemia. DZX should
be avoided in diabetic patients at risk of ischemic events. (J Am Coll Cardiol 2015;66:1144–56) © 2015 by the American
College of Cardiology Foundation.T ype 2 diabetes mellitus (T2DM) is a mul-tifactorial disease process that encompasseshyperglycemia, dyslipidemia, and hyper-
insulinemia. Collectively, these factors produce a
malignant environment marked by oxidative stress
(1). Although patients with T2DM are more vulnerable
to ischemic injury than nondiabetic people (2), the
detailed electrophysiological substrate of T2DM
hearts and their response to ischemia are poorly
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AB BR E V I A T I O N S
AND ACRONYM S
APD = action potential
duration
APD75 = action potential
duration at 75% of
repolarization
CV = conduction velocity
DZX = diazoxide
KATP channel = adenosine
triphosphate-sensitive
potassium channel
mKATP = mitochondrial
adenosine triphosphate-
sensitive potassium
mRNA = messenger
ribonucleic acid
PCL = pacing cycle length
PCR = polymerase chain
reaction
ROMK = renal outer medullary
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1145beta cell rest and inhibition of apoptosis (5). These
mechanistic studies in animal models are being
rapidly translated to humans. In a proof-of-principle
trial, healthy people who received oral DZX
(4 mg/kg) exhibited a 30% decrease in glucose pro-
duction, with no difference in the rate of glucose
uptake compared with placebo-treated counterparts
(6). Moreover, DZX reversed weight gain in pre-
diabetic obese, hyperinsulinemic people (7,8). The
therapeutic utility of DZX was also tested in patients
with type 1 diabetes mellitus (T1DM) (9) and in those
undergoing coronary bypass surgery (10). Radtke
et al. (9) reported that treatment of newly diagnosed
T1DM patients with DZX for 6 months improved their
glycemic control without affecting their beta cell
function. Finally, in a double-blinded randomized
study, supplementation of cardioplegia with low-
dose DZX protected cardiac mitochondria, meta-
bolism, and function in patients undergoing cardiac
bypass surgery (10).TABLE 1 Average BW, HW, Ratio of BW to HW, and
Blood Glucose Levels of T2DM and Control Animals
T2DM Control
BW (g) 410  65 283  29
HW (g) 1.6  0.1 1.2  0.1
HW/BW, mg/g 3.9  0.3 4.3  0.2
Glucose, mg/dl 408  119 128  14
Age, weeks 13–16 13–14
BW ¼ body weight; HW ¼ heart weight; T2DM ¼ type 2 diabetes mellitus.
SEE PAGE 1157
potassium channel
SprD = Sprague-Dawley
T1DM = type 1 diabetes
mellitus
T2DM = type 2 diabetes
mellitus
VT = ventricular
tachyarrhythmia
ZL = Zucker lean (rat)
ZO = Zucker obese diabetic
fatty (rat)These highly encouraging clinical ﬁndings likely
stem from the activation of cardioprotective signaling
via mitochondrial adenosine triphosphate-sensitive
potassium (mKATP) channels by DZX (11–19). Howev-
er, at high concentrations (300 mmol/l), DZX was
shown to promote arrhythmias in coronary-perfused
atria and ventricles from failing and nonfailing hu-
man hearts by activating sarcolemmal (as opposed to
mitochondrial) KATP channels (20).
We hypothesized that owing to its dual nature as
an antidiabetic and cardioprotective agent, low-dose
(30 mmol/l) DZX may be particularly useful in sup-
pressing ischemia-related arrhythmias in T2DM
without altering basal electrophysiology. Contrary
to our original hypothesis, we uncovered a potent
proarrhythmic effect of DZX exclusively in T2DM
hearts during challenge with ischemia. Our ﬁndings
raise major concerns regarding the safety proﬁle of
mKATP channel activation in T2DM patients at risk of
ischemic injury.
METHODS
EXPERIMENTAL RAT MODEL OF T2DM. All pro-
cedures involving animal handling were approved by
the Animal Care and Use Committee of the Icahn
School of Medicine at Mount Sinai and adhered to the
Guide for the Care and Use of Laboratory Animals
published by the U.S. National Institutes of Health.
All animals were purchased from the Charles River
Laboratory (Wilmington, Massachusetts). We used12- to 16-week-old male Zucker obese diabetic
fatty (fa/fa) rats (ZO) (n ¼ 43) as a standard
model of established insulin resistance and
T2DM. This model faithfully recapitulates
hallmark features of the clinical disease,
including hyperinsulinemia, dyslipidemia,
and hyperglycemia (21). Age- and sex-
matched Zucker lean (ZL) (n ¼ 13) and
normal Sprague-Dawley (SprD) (n ¼ 30) rats
were also used. In a subset of experiments
involving 6 ZL and 7 SprD rats, we found no
signiﬁcant differences in electrophysiological
parameters, including action potential dura-
tion at 50%, 75% (APD75), and 90% of repo-
larization and conduction velocity (CV).
Marked hyperglycemia and weight gain in the
absence of hypertrophy were conﬁrmed in
T2DM compared with control rats (Table 1).
OPTICAL ACTION POTENTIAL MAPPING OF
EX VIVO PERFUSED HEARTS. Hearts were
excised rapidly and Langendorff perfused
with Tyrode’s solution containing 121.7
mmol/l NaCl, 25.0 mmol/l NaHCO3, 2.74
mmol/l MgSO4, 4.81 mmol/l KCl, 5.0 mmol/l
dextrose, and 2.5 mmol/l CaCl2 (pH 7.40; 95%
O2/5% CO2). Atria were removed to avoid
competitive stimulation of the ventricles.
Perfusion pressure was maintained at 60 to
70 mm Hg by regulating coronary perfusion
ﬂow.
Preparations were placed in a custom-built
tissue bath and pressed gently against a glass imaging
window by a stabilizing piston (22–26). Movement
was suppressed by perfusion with blebbistatin 10
mmol/l for 10 to 15 min. To avoid surface cooling,
preparations were immersed in the coronary efﬂuent
maintained at a physiological temperature by a heat
exchanger assembly (22). Cardiac rhythm was moni-
tored continuously via silver electrodes connected to
an electrocardiogram ampliﬁer. Cardiac rhythm,
perfusion pressure, and ﬂow were monitored
continuously during each experiment.
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80  80-pixel charge-coupled device camera coupled
to an imaging macroscope that contained a high
numerical aperture lens, a dichroic mirror, excita-
tion and emission ﬁlters, a beam splitter, and a
light-collimating tube. Excitation light was provided
by a low-noise, high-power tungsten-halogen lamp
and directed in an epiﬂuorescence conﬁguration onto
the heart through a side port of the macroscope in a
manner that minimized heterogeneity of incident
light across the mapped 8  8 mm2 region. Emitted
light was collected by the front lens of the macro-
scope, ﬁltered, and directed onto the charge-coupled
device detector. High-resolution optical action po-
tentials were measured simultaneously from 6,400
sites during each recording. To improve signal qual-
ity, spatial binning was performed, which yielded an
array of 400 (20  20) high-ﬁdelity optical action
potentials that were amenable to accurate automated
analyses.
EXPERIMENTAL PROTOCOL. Hearts from control
(SprD, ZL) and T2DM (ZO) rats underwent steady-
state pacing at a wide range of pacing cycle lengths
(PCLs) (300 to 100 ms, in 20-ms decrements) during
baseline perfusion. Subsequently, hearts underwent
ischemia-reperfusion injury while being paced at a
PCL of 300 ms. We chose a 12-min global no-ﬂow
ischemia challenge because we found in a pilot
study that this protocol gave rise to sustained post-
ischemic arrhythmias within 1 min of reperfusion in
w50% of hearts. This rate of post-ischemic arrhyth-
mias allows one to examine whether a given drug
decreases or increases the incidence of arrhythmias.
Untreated hearts were perfused with normal Tyrode’s
solution throughout the entire protocol, except for
the 12-min ischemia phase. DZX-treated hearts were
initially perfused with normal Tyrode’s solution, fol-
lowed by Tyrode’s containing DZX 30 mmol/l.
ELECTROPHYSIOLOGICAL MEASUREMENTS. Conduct ion
veloc i ty . As detailed previously (23,24), conduction
delays were assessed by recording action potentials
during steady-state pacing. Local activation time at
each site was deﬁned as the maximum ﬁrst derivative
during the upstroke of the action potential. Velocity
vectors (magnitude and direction) were derived from
the activation times of each pixel relative to those of
its neighbors. CV was measured by averaging the
magnitude of the velocity vectors along the longitu-
dinal and transverse axes. The anisotropic ratio was
deﬁned as the ratio of fast (longitudinal) divided by
slow (transverse) CV.
Act ion potent ia l durat ion . Repolarization times at
75% and 90% relative to the action potentialamplitude were quantiﬁed. Action potential duration
(APD) was deﬁned as the temporal difference be-
tween the repolarization and activation times at each
site.
REAL-TIME POLYMERASE CHAIN REACTION
MEASUREMENTS. Tissue specimens from SprD (n¼ 3),
ZL (n ¼ 3), and ZO (n ¼ 3) hearts were used to measure
messenger ribonucleic acid (mRNA) expression
levels of the alpha (Kir6.1, Kir6.2) and beta (SUR1A,
SUR1B, SUR2A, SUR2B) subunits that constitute
the KATP channel, as well as the 2 cardiac isoforms of
the renal outer medullary potassium channel
(ROMK1 and ROMK2). Total ribonucleic acid was
extracted by acid guanidinium thiocyanate-phenol-
chloroform using TRIzol reagent (Life Technologies,
Carlsbad, California). One microgram of total ribo-
nucleic acid was reverse transcribed into ﬁrst-strand
complementary deoxyribonucleic acid by use of a
high-capacity complementary deoxyribonucleic acid
reverse transcription kit with ribonuclease inhibitor.
Real-time polymerase chain reactions (PCR) were
performed with the Applied Biosystems 7500 system
and Power SYBR Green PCR Master Mix (Applied
Biosystems, Waltham Massachusetts) in triplicate.
High-resolution melting curves were generated to
conﬁrm the speciﬁcity of PCR products. Threshold
cycle (CT) values were determined after rectiﬁcation
by the passive reference dye Rox within the master
mix. mRNA expression levels were evaluated by the
2-DCT method. Levels of KATP channel subunits were
normalized to those of the internal control, beta-
actin.
STATISTICAL ANALYSES. Summary data are pre-
sented as mean  SD. Welch’s unpaired t test was
used to detect differences in blood glucose levels
between T2DM and controls. The Student t test was
used to compare electrophysiological parameters be-
tween T2DM and control hearts. The paired t test was
used to compare groups before and after drug treat-
ment. One-way analysis of variance was used to
compare differences between more than 2 groups.
A Fisher exact test was used to compare differences
in susceptibility to arrhythmias. Differences were
considered signiﬁcant at p < 0.05.
RESULTS
BASAL ELECTROPHYSIOLOGICAL PROPERTIES OF
T2DM AND CONTROL ANIMALS. Figure 1 shows
representative optical action potentials recorded
from control (SprD, ZL) and T2DM (ZO) rats during
steady-state pacing at a PCL of 300 ms. On average,
ZO rat hearts exhibited a trend toward prolonged
(by 18.5%; p ¼ 0.052) APD75 compared with controls
FIGURE 1 Baseline Electrophysiological Properties of T2DM and Control Hearts
n=6 n=6 n=6n=6
n=6
n=6 n=4
n=4 n=6 n=4
B
A Control T2DM
T2DM
Control
ZOSprD ZL
Average APD75
(PCL=300ms)
APD75 Range APD75 Std Dev
Longitudinal Transverse
Ratio
An
iso
tr
op
ic
Ra
tio
(m
s)
(m
s)
CV
 (c
m
/s
ec
)
APD Heterogeneity
(PCL=300ms)
C
ED
100
40 8
6
4
2
0
150
100
50
0
4
3
2
1
0
200ms
20
30
10
0
80 p = 0.052 p = 0.632 p = 0.863
60
40
20
0
0 15 ms
LV RV
Ap
ex
Ba
se
8mm
Depolarization Time (ms)
50ms
Control
SprD 1
ZO 1 ZO 2 ZO 3 ZO 4
SprD 2 SprD 3 SprD 4
Co
nt
ro
l
T2DM
T2
DM
Control Control
Control
Control
ControlT2DM T2DM
T2DM
T2DM T2DM
n=6 n=6
(m
s)
(A) Representative optical action potentials recorded during steady-state pacing of hearts from control rats (Sprague-Dawley [SprD] and Zucker lean [ZL])
and rats with type 2 diabetes mellitus (T2DM) (Zucker obese diabetic fatty [ZO]). (B) Average action potential duration measured at 75% of repolarization
(APD75) at pacing cycle length (PCL) of 300 ms. Analysis is based on 6 ZL and 6 ZO rats. (C) Range and standard deviation (Std Dev) of APD75 values
measured across the mapping ﬁeld as independent indices of APD heterogeneity. (D) Representative isochrone maps illustrating the elliptical spread of
the impulse across the epicardial surface. (E) Average longitudinal and transverse conduction velocities and the anisotropic ratio of control and T2DM hearts.
CV ¼ conduction velocity; LV ¼ left ventricle; RV ¼ right ventricle.
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1147(Figure 1B). No signiﬁcant differences (p ¼ 0.65) in
APD75 were found between ZL (46.1  7.0 ms) and
SprD (47.9  3.0 ms) hearts. APD heterogeneity
indexed by the range and standard deviation of APD75
values over an 8  8 mm2 region of each heart
revealed no signiﬁcant differences between T2DM
and controls for either metric (Figure 1C).
Figure 1D shows representative isochrone maps
depicting the elliptical spread of the action potential
wave front across the epicardium in control and
T2DM hearts. There were no signiﬁcant differences in
longitudinal CV (p ¼ 0.205), transverse CV (p ¼ 0.156),or their ratio (p ¼ 0.13) between T2DM and control
hearts (Figure 1E). Finally, programmed electrical
stimulation with single premature stimuli (S2) was
performed in a subset of 4 ZO hearts. S2 coupling
intervals were initially varied in 10-ms decrements,
followed by 2-ms increments to resolve local refrac-
toriness. No arrhythmias were observed when this
protocol was used (not shown).
ELECTROPHYSIOLOGICAL RESPONSE OF T2DM HEARTS
TO ISCHEMIA. Patients with T2DM are highly suscep-
tible to ischemic injury. We therefore tested whether
ischemia-mediated electrophysiological remodeling
FIGURE 2 Differential APD Response to Ischemia in Control Versus T2DM Hearts
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(A) Representative action potential traces before and 12 min after ischemia in control hearts (purple) and hearts of rats with T2DM (red). (B) Representative
APD75 contour maps measured before and after 12 min of ischemia from control and T2DM hearts. (C) Representative action potential traces recorded
at baseline and during no-ﬂow ischemia. (D) Average action potential duration measured at 90% of repolarization (APD90) in control and T2DM hearts
showing sustained shortening in the former group (purple) and a biphasic response in the latter (red). Superimposed action potential traces from
representative T2DM (red) and control (purple) hearts at 12 min of ischemia. Controls consisted of SprD (n ¼ 3) and ZL (n ¼ 6) animals; T2DM was ZO
animals (n ¼ 4). APD ¼ action potential duration; other abbreviations as in Figure 1.
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1148was more severe in hearts from T2DM rats compared
with control animals. Figures 2A and 2B show repre-
sentative action potential traces and APD contour
maps measured from control (SprD, ZL) and T2DM
(ZO) hearts before and 12 min after no-ﬂow ischemia.
As expected, no-ﬂow ischemia resulted in signiﬁcant
APD shortening in hearts from control animals
(Figures 2A to 2C). In sharp contrast, hearts from
T2DM animals did not undergo progressive APD
adaptation in response to an identical ischemic
challenge (Figures 2A to 2C). Instead, they exhibited a
biphasic response, because early APD shortening was
fully reversed during the latter phase (9 to 12 min) of
ischemia (Figure 2D).We next investigated potential differences in
ischemia-mediated conduction slowing between
groups. Figure 3A shows isopotential contour maps
recorded at 1-ms intervals before (baseline) and 12 min
after ischemia in control (SprD, ZL), and T2DM (ZO)
hearts. Figure 3B shows representative action poten-
tial upstrokes (ﬁrst derivatives) measured from equi-
distant sites. Figure 3C presents average CV during
baseline perfusion and after ischemic challenge. As
expected, ischemia resulted in signiﬁcant CV slowing
in all groups. Interestingly, a trend toward a greater
percentage reduction of CV by ischemia was noted for
T2DM rats than for controls (Figure 3D); however, this
trend did not reach statistical signiﬁcance (p ¼ 0.243).
FIGURE 3 Conduction Slowing in Response to Ischemia in Control and T2DM Hearts
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(A) Representative series of isopotential contour maps recorded at 1-ms intervals indicate the sequential spread of depolarization before and after the
ischemic challenge in SprD, ZL, and ZO hearts. Each frame is 8  8 mm2. (B) Representative action potential ﬁrst derivatives recorded from equidistant sites
across the mapping ﬁeld. (C) Average CV measurements at baseline and after 12 min of ischemia in control and T2DM hearts. (D) Percentage change in
CV after 12 min of ischemia relative to baseline in control and T2DM (ZO) hearts. Controls were SprD (n ¼ 3) and ZL (n ¼ 6) animals; T2DM was ZO animals
(n ¼ 4). Abbreviations as in Figure 1.
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1149Finally, after the 12-min ischemia protocol, 4 of
9 control and 3 of 5 T2DM hearts underwent sus-
tained arrhythmias within 1 min of reperfusion
(not shown).
DZX PARADOXICALLY PROMOTES ARRHYTHMIAS IN
T2DM. The main purpose of our study was to deter-
mine whether low-dose DZX, which improves meta-
bolic function in experimental models and in
humans, would prevent arrhythmias in T2DM. We
therefore examined its effects on key electrophysio-
logical properties before and during challenge of
T2DM hearts with ischemia.
Figure 4A shows the average APD75 rate relation-
ships in untreated and DZX-treated T2DM hearts
during baseline perfusion. Clearly, DZX 30 mmol/l did
not alter baseline APD values at any PCL (Figure 4A),which discounts a role for nonischemic activation of
sarcolemmal KATP channels.
We next investigated potential differences in the
response of untreated and DZX-treated T2DM hearts
to ischemia. Although APD75 of untreated T2DM
hearts failed to shorten progressively in response to
ischemia (Figure 4B), DZX treatment caused rapid and
sustained APD shortening during the course of
ischemia (Figure 4B). On average, APD75 of DZX-
treated T2DM hearts was shorter by 32.6% (p < 0.01)
after 6 min of ischemia compared with their un-
treated counterparts (Figure 4B).
The heightened sensitivity of DZX-treated T2DM
hearts to ischemia-induced APD shortening was likely
signiﬁcant, because all 7 DZX-treated but none of the
5 untreated T2DM hearts exhibited onset of sustained
FIGURE 4 Proarrhythmic Effect of DZX in T2DM
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1150ventricular tachyarrhythmia (VT) during the latter
phase (10 to 12 min) of ischemia (Figure 4C). More-
over, none of the 9 untreated or 7 DZX-treated control
hearts exhibited VT during ischemia (Figure 4C).
As such, DZX provoked VT exclusively in T2DM hearts
during ischemia (Figure 4C). Figure 4D shows indi-
vidual measurements of APD75, either before the
onset of VT in DZX-treated T2DM hearts or at the end
of the 12-min ischemic challenge in untreated T2DM
hearts. In all cases, APD75 of untreated T2DM hearts
was longer after 12 min of ischemia than that of DZX-
treated T2DM hearts, which underwent a 26% to 56%
reduction before the onset of VT.
We investigated the potential mechanism underly-
ing the selective proarrhythmic effect of DZX on T2DMhearts. Whereas on average, DZX-treated T2DM hearts
exhibited a minor trend toward longer APD75 values
during ischemia than DZX-treated controls, differ-
ences were not statistically signiﬁcant (Figure 5A). In
contrast, APD heterogeneity, as indexed by the stan-
dard deviation and range of APD75 values across the
mapping ﬁeld, was more than 2-fold greater in DZX-
treated T2DM than in DZX-treated control hearts at
8 and 10 min of ischemia (Figure 5A). Figure 5B shows
representative APD contour maps that illustrate the
greater APD heterogeneity at 8 min of ischemia in
DZX-treated T2DM than in control hearts. Figure 5C
shows representative histograms that illustrate the
wider distribution of APD75 values in individual DZX-
treated T2DMhearts than in their control counterparts.
FIGURE 5 APD Response to DZX Treatment in Control and T2DM Hearts
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(A) Average APD75, APD75 range, and APD75 standard deviation at 8 min and 10 min of ischemia in DZX-treated control and T2DM hearts. (B) Representative APD75
contour maps from control and T2DM hearts at 8 min of ischemia. (C) Representative histograms showing the distribution of APD75 values across the mapping ﬁeld in
individual DZX-treated control and DZX-treated T2DM hearts at 8 min of ischemia. Controls were 3 ZL and 3 SprD rats; T2DM was 5 ZO rats. APD ¼ action potential
duration; other abbreviations as in Figures 1 and 3.
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1151We next compared the electrophysiological ef-
fects of DZX with those of the classic SUR2A activator
pinacidil. Unlike DZX, which did not affect base-
line APD75 in either group, pinacidil 100 mmol/l
caused signiﬁcant APD75 shortening in T2DM hearts
(p ¼ 0.047) and a strong trend toward shorter levels in
controls (p ¼ 0.069) during baseline perfusion
(Figure 6A). Pinacidil also promoted the rapid (within
6 to 7 min) onset of VT during ischemia in bothcontrol and T2DM hearts (Figure 6B), whereas DZX
only exerted a proarrhythmic effect in T2DM
(Figure 5). Profound action potential shortening was
evident by 5 min of ischemia in pinacidil-treated
control and T2DM hearts (Figure 5C).
EXPRESSION OF KATP CHANNEL SUBUNITS. To
determine whether the proarrhythmic effect of DZX
in T2DM hearts was related to altered expression of
KATP channels, we measured the mRNA expression
FIGURE 6 Effects of Pinacidil on Control and T2DM Hearts
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(A) Average APD75 values for control (n ¼ 4) and T2DM (n ¼ 4) hearts before and after treatment with DZX (30 mmol/l) or pinacidil (100 mmol/l). (B)
Summary of VT propensity during ischemia in untreated and pinacidil-treated control and T2DM hearts. Arrhythmogenesis during early ischemia was
provoked by pinacidil treatment in both control and T2DM hearts. (C) Representative action potential traces revealing profound action potential shortening
at 5 min of ischemia in pinacidil-treated control and T2DM hearts. PIN ¼ pinacidil; other abbreviations as in Figures 1 and 3.
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1152levels of all known KATP channel subunits using real-
time PCR. Figure 7A shows the normalized (to beta-
actin) mRNA expression of the alpha (Kir6.1 and
Kir6.2) and beta (SUR1A, SUR1B, SUR2A, and SUR2B)
subunits of the KATP channel in SprD, ZL, and ZO
hearts. We found that samples from ZL and ZO
animals exhibited a trend toward increased expres-
sion of most KATP channel subunits compared
with their SprD counterparts (Figure 7A); however,
this apparent up-regulation only reached statistical
signiﬁcance in the case of SUR2B between ZO and
SprD animals (Figure 7A). Importantly, there were no
signiﬁcant differences in the expression of any of
these subunits between ZL and ZO hearts (Figure 7A).
As such, none of the observed changes could explain
the proarrhythmic effect that was exclusive to ZO
animals.
A recent study highlighted the potential impor-
tance of ROMK (KCNJ1) in formation of the mKATP
channel (27). We therefore measured the mRNA
levels of the 2 ROMK isoforms (ROMK1 and ROMK2)that are expressed in the heart. We found no sig-
niﬁcant differences in the expression levels of
either isoform between groups (Figure 7B). Primers
used for mRNA measurements are shown in
Figure 7C.
DISCUSSION
We investigated the electrophysiological conse-
quences of ischemia in T2DM and tested whether low-
dose DZX, a potent activator of cardioprotective
signaling (11–19), could improve electrical function in
that setting. Our major ﬁndings were as follows:
1) during normoxic perfusion, T2DM hearts are stable,
exhibiting only minor electrophysiological changes;
2) in response to ischemia, T2DM hearts are charac-
terized by repolarization resistance, because their
average APD fails to exhibit progressive shortening;
3) DZX treatment exacerbates arrhythmias ex-
clusively in T2DM hearts by promoting rapid and
heterogeneous APD shortening during ischemia
FIGURE 7 KATP Channel Subunit Expression in Control and T2DM Hearts
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(A) Messenger RNA (mRNA) expression of Kir6.1, Kir6.2, SUR1A, SUR1B, SUR2A, and SUR2B measured by real-time polymerase chain
reaction (RT-PCR) in SprD (n ¼ 3), ZL (n ¼ 3), and ZO (n ¼ 3) animals. (B) mRNA expression of ROMK1 and ROMK2 measured by RT-PCR in SprD
(n ¼ 3), ZL (n ¼ 3), and ZO (n ¼ 3) animals. (C) Primers used for RT-PCR measurements. Beta-actin was used as a normalizing control.
KATP ¼ adenosine triphosphate-sensitive potassium channel; other abbreviations as in Figure 1.
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1153(Central Illustration); and 4) changes in the mRNA
expression of KATP channel subunits do not cause
these phenotypic differences.
STABILITY OF BASAL ELECTROPHYSIOLOGICAL
PROPERTIES IN T2DM. Our initial objective was to
deﬁne the electrophysiological substrate of hearts
from obese T2DM animals. We focused on conduction
slowing and APD prolongation as potentially impor-
tant features of pathological electrical remodeling.
Surprisingly, we found only modest changes in APD
and CV in this established model of obesity and
T2DM. As such, our present ﬁndings discount a major
role for these basal electrophysiological properties in
the proarrhythmic vulnerability of the diabetic heart.
Our present ﬁndings are reminiscent of our previous
ﬁndings in a guinea pig model of streptozotocin-
induced T1DM, in which arrhythmias were only
encountered on depletion of the scavenging capacity
of the heart (28).
ALTERED APD ADAPTATION DURING ISCHEMIA:
REPOLARIZATION RESISTANCE IN T2DM? Because
patients with T2DM are highly susceptible to the
complications of coronary artery disease, wespeculated that acute ischemia might unmask the
electrophysiological vulnerability of these hearts. A
major ﬁnding of the present report was the failure of
T2DM hearts to exhibit progressive APD adaptation
(shortening) in response to 12 min of no-ﬂow
ischemia. The mechanism underlying this repolari-
zation resistance will require additional investiga-
tion, although it suggests down-regulation of
sarcolemmal KATP channels, resulting from either
reduced expression or function of these channels.
Interestingly, Ren et al. (29) found a marked reduc-
tion in SUR2A mRNA expression in a model of T1DM.
We measured the transcript levels of all known alpha
and beta subunits of KATP channels, including Kir6.1,
Kir6.2, SUR1A, SUR1B, SUR2A, SUR2B, ROMK1, and
ROMK2. An important advantage of our experimental
design was the use of 2 different control groups that
were functionally identical but genetically distinct.
Speciﬁcally, ZL controls share a common genetic
background with their ZO counterparts but are func-
tionally identical (in terms of electrophysiology, heart
weight, body weight, and blood glucose levels) to
age-matched SprD animals. By measuring changes in
CENTRAL ILLUSTRATION DZX-Mediated Arrhythmias in T2DM: Proarrhythmic Effect of DZX in Rats
Xie, C. et al. J Am Coll Cardiol. 2015; 66(10):1144–56.
The proarrhythmic effect of mitochondrial adenosine triphosphate-sensitive potassium (mKATP) channel activation by low-dose diazoxide (DZX) in hearts from rats with
type 2 diabetes mellitus (T2DM) is illustrated. Electrophysiological properties were stable at baseline but revealed impaired adaptation to increased metabolic demand
during acute ischemia in diabetic (red) compared with nondiabetic (blue) rats. The classically cardioprotective agent DZX caused paradoxical exacerbation of arrhythmias
in diabetic but not normal animals, owing to a rapid and spatially heterogeneous shortening of action potentials across the heart, which in turn, created a substrate for
reentrant ventricular tachyarrhythmia. APD ¼ action potential duration; APD75 ¼ action potential duration at 75% of repolarization.
Xie et al. J A C C V O L . 6 6 , N O . 1 0 , 2 0 1 5
Diazoxide-Mediated Arrhythmias in Diabetes S E P T E M B E R 8 , 2 0 1 5 : 1 1 4 4 – 5 6
1154the mRNA expression of KATP channel subunits in all 3
groups, we were able to determine whether a given
change was functionally important. Surprisingly, we
only found a signiﬁcant change in the expression of
SUR2B between ZO and SprD animals. Therefore, our
data indicate that the unique functional response of
T2DM hearts to ischemia is unrelated to the transcript
levels of KATP channel subunits. This suggests
involvement of post-transcriptional mechanisms that
regulate protein synthesis, trafﬁcking, insertion, sta-
bility, or gating of these channels. Of note, AMP-
activated protein kinase (AMPK) signaling has been
implicated in preconditioning-induced shortening of
the action potential through effects on KATP channel
activity and recruitment (30). Moreover, drugs that
activate AMPK signaling are a mainstay of treatment
of T2DM patients (31). Impaired AMPK in T2DM may
contribute to repolarization resistance. Clearly,
identiﬁcation of the exact molecular mechanismsunderlying impaired APD adaptation of T2DM hearts
to ischemia warrants investigation.
DZX FOR TREATMENT OF DIABETES MELLITUS. In a
recent clinical study, DZX suppressed endogenous
glucose production (6). The presumed antidiabetic
efﬁcacy of DZX has been linked to preservation of
pancreatic beta cells through promotion of beta cell
rest and inhibition of apoptosis. Indeed, pilot clinical
trials using DZX have demonstrated improvement of
metabolic function in pre-diabetic obese, hyper-
insulinemic patients and in those with T1DM (7–9).
Numerous experimental studies have established
DZX as a potent cardioprotective agent that reduces
reperfusion injury by promoting activation of bene-
ﬁcial mitochondrial pathways (11–19). Indeed, a pilot
study demonstrated that supplementation of car-
dioplegia with DZX improved the outcome of patients
undergoing coronary bypass surgery (10); however,
the infarct-sparing efﬁcacy of DZX in diabetes is less
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The mito-
chondrial KATP channel agonist DZX exerts salutary myocardial
protective effects against ischemic injury, produces vasodila-
tion in hypertensive patients, and reverses hypoglycemic
complications in patients with T2DM. However, in an animal
model of T2DM with impaired electrophysiological adaptation
to acute ischemia, DZX elicited proarrhythmic effects because
of the rapid, heterogeneous shortening of the action potential
unrelated to transcript levels of ATP-sensitive potassium
channels.
TRANSLATIONAL OUTLOOK: Agents considered safe and
effective in structurally normal hearts might be associated with
proarrhythmic risks in the setting of diabetes mellitus. Strategies
to mitigate the proarrhythmic effects of mitochondrial KATP
channel agonists should be investigated in patients with T2DM at
risk of myocardial ischemia.
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1155clear, because DZX failed to reduce infarct size after
30 min of left anterior descending coronary artery
occlusion in T2DM animals (32). This is consistent
with the notion that cardioprotective stimuli (such as
ischemic preconditioning), which likely depend on
mKATP channels, are defective in diabetes (33).
Although the infarct-sparing effects of DZX have
been widely studied, there are no reports of its role in
the modulation of electrophysiological properties of
T2DM hearts. A major ﬁnding of the present report
was that DZX elicited a potent proarrhythmic effect
exclusively in the setting of diabetes, because all
DZX-treated T2DM hearts but none of the untreated
T2DM or control hearts exhibited sustained ischemia-
mediated VT. We used a widely accepted DZX con-
centration (30 mmol/l) that is relatively speciﬁc for the
mitochondrial pool of KATP channels (15–19). At this
concentration, DZX did not alter basal electrophysi-
ological properties. The lack of effect of low-dose DZX
on baseline APD strongly discounts a role for nonse-
lective activation of sarcolemmal KATP channels in the
proarrhythmic effect that we uncovered. Unlike DZX,
the classic SUR2A-speciﬁc KATP channel activator,
pinacidil, provoked ischemia-mediated VT in all
hearts (T2DM and control), consistent with previous
ﬁndings in failing and nonfailing human heart prep-
arations (20). Finally, the lack of arrhythmia protec-
tion by DZX in T2DM hearts on ischemic challenge is
consistent with the lack of protection against
myocardial infarction by ischemic preconditioning
and DZX (33).
CONCLUSIONS
Our current study raises important safety concerns
regarding the use of DZX in diabetic patients(Central Illustration). Speciﬁcally, a potent proar-
rhythmic effect during ischemic challenge should
caution against the rapid translation of DZX-based
therapies for the treatment of T2DM patients, who
are indeed at high risk of coronary artery disease,
acute myocardial infarction, and silent myocardial
ischemia (4,34–36).
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